Photobiomodulation therapy to treat a degenerative condition of the retina and/or the optic nerve
US11253722B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Oct 30, 2019 |
| Grant date | Feb 22, 2022 |
| Priority date | — |
| Expiry date | Oct 30, 2039 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61N2005/0662
- WIPO fieldMedical technology
- WIPO sectorInstruments
Abstract
Photobiomedulation therapy (PBMT) can be applied to the eye to treat optical neuritis, a sign of multiple sclerosis (MS). The light of PBMT can be directed into the eye, regardless of the position of the eye, by a device that includes an array of light delivery devices and a heat sink lens. The device can be placed proximal to the eye to direct the light into the eye. The light can have one or more wavelengths from 400-1100 nm and can be applied in at least one of a pulsed operating mode, a continuous operating mode, and a super-pulsed operating mode through the light source device to the skeletal muscle. The light signal is applied for a time sufficient to stimulate a phototherapeutic response in the retina and/or the optic nerve. PBMT applied in this manner provides a noninvasive, safe and effective treatment for optic neuritis.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.